BR112012016330A2 - ativadores de tieno [2, 3-b] piridinadiona de ampk e usos terapêuticos dos mesmos - Google Patents

ativadores de tieno [2, 3-b] piridinadiona de ampk e usos terapêuticos dos mesmos

Info

Publication number
BR112012016330A2
BR112012016330A2 BR112012016330A BR112012016330A BR112012016330A2 BR 112012016330 A2 BR112012016330 A2 BR 112012016330A2 BR 112012016330 A BR112012016330 A BR 112012016330A BR 112012016330 A BR112012016330 A BR 112012016330A BR 112012016330 A2 BR112012016330 A2 BR 112012016330A2
Authority
BR
Brazil
Prior art keywords
ampk
activators
pyridinedione
thieno
therapeutic uses
Prior art date
Application number
BR112012016330A
Other languages
English (en)
Other versions
BR112012016330B8 (pt
BR112012016330B1 (pt
Inventor
Charon Christine
Cravo Daniel
Lepifre Franck
Durand Jean-Denis
Faveriel Laurent
Hallakou-Bozec Sophie
Bolze Sébastien
Original Assignee
Poxel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poxel filed Critical Poxel
Publication of BR112012016330A2 publication Critical patent/BR112012016330A2/pt
Publication of BR112012016330B1 publication Critical patent/BR112012016330B1/pt
Publication of BR112012016330B8 publication Critical patent/BR112012016330B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ativadores de tieno [2, 3-b] piridinadiona de ampk e usos terapêuticos dos mesmos. a invenção refere-se a compostos que são ativadores diretos de ampk (proteína cinase ativada por amp) e seu uso no tratamento de distúrbios regulados por ativação de ampk. por exemplo, compostos de acordo com a invenção são úteis para o tratamento de diabetes, síndrome metabólica, obesidade, inflamação, câncer e doenças cardiovasculares.
BR112012016330A 2009-12-29 2010-12-28 ativadores de tieno [2, 3-b] piridinadiona de ampk e composição farmacêutica compreendendo os mesmos BR112012016330B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09306344,4 2009-12-29
EP09306344 2009-12-29
PCT/EP2010/070811 WO2011080277A1 (en) 2009-12-29 2010-12-28 Thieno [2,3-b] pyridinedione activators of ampk and therapeutic uses thereof

Publications (3)

Publication Number Publication Date
BR112012016330A2 true BR112012016330A2 (pt) 2018-04-03
BR112012016330B1 BR112012016330B1 (pt) 2021-03-23
BR112012016330B8 BR112012016330B8 (pt) 2021-05-25

Family

ID=41691577

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012016330A BR112012016330B8 (pt) 2009-12-29 2010-12-28 ativadores de tieno [2, 3-b] piridinadiona de ampk e composição farmacêutica compreendendo os mesmos

Country Status (24)

Country Link
US (1) US9365584B2 (pt)
EP (1) EP2519527B1 (pt)
JP (1) JP5559894B2 (pt)
KR (1) KR101469002B1 (pt)
CN (1) CN102803269B (pt)
AU (1) AU2010338280B2 (pt)
BR (1) BR112012016330B8 (pt)
CA (1) CA2784553C (pt)
CY (1) CY1114952T1 (pt)
DK (1) DK2519527T3 (pt)
EA (1) EA020588B1 (pt)
ES (1) ES2445537T3 (pt)
HR (1) HRP20140035T1 (pt)
IL (1) IL220432A (pt)
ME (1) ME01558B (pt)
MX (1) MX2012007548A (pt)
PL (1) PL2519527T3 (pt)
PT (1) PT2519527E (pt)
RS (1) RS53282B (pt)
SI (1) SI2519527T1 (pt)
SM (1) SMT201400013B (pt)
TW (1) TWI574968B (pt)
WO (1) WO2011080277A1 (pt)
ZA (1) ZA201205604B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2776038T1 (en) 2011-11-11 2018-06-29 Gilead Apollo, Llc ACC INHIBITORS AND THEIR USE
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
WO2015103480A1 (en) 2014-01-02 2015-07-09 Massachusetts Eye & Ear Infirmary Treating ocular neovascularization
WO2017011917A1 (en) * 2015-07-23 2017-01-26 Thrasos Therapeutics Inc. Methods for treating and preventing polycystic kidney diseases (pkd) using amp-activated protein kinase (ampk) modulators and activators
AR106472A1 (es) 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
CA3004747A1 (en) 2015-11-25 2017-06-01 Gilead Apollo, Llc Fungicidal compositions containing derivatives of 2,4-dioxo-1,4-dihydrothieno[2,3-d]pyrimidine
ES2939977T3 (es) 2015-11-25 2023-04-28 Gilead Apollo Llc Inhibidores de triazol ACC y usos de los mismos
EP3380480B1 (en) 2015-11-25 2022-12-14 Gilead Apollo, LLC Pyrazole acc inhibitors and uses thereof
HUE053175T2 (hu) 2015-11-25 2021-06-28 Gilead Apollo Llc ACC-gátló észterek és azok alkalmazása
CA3155220C (en) 2016-03-02 2024-01-16 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
WO2018045969A1 (zh) * 2016-09-07 2018-03-15 法玛科技顾问股份有限公司 活化腺苷单磷酸活化蛋白激酶之化合物
ES2927019T3 (es) 2017-03-28 2022-11-02 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de enfermedades hepáticas
WO2019185413A1 (en) 2018-03-27 2019-10-03 Basf Se Pesticidal substituted cyclopropyl derivatives
BR112022023359A2 (pt) 2020-05-19 2023-04-18 Kallyope Inc Ativadores de ampk
EP4172162A1 (en) 2020-06-26 2023-05-03 Kallyope, Inc. Ampk activators
EP4221700A1 (en) 2020-09-30 2023-08-09 Bioverativ Therapeutics Inc. Ampk activators and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119205B2 (en) * 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
BRPI0910439B8 (pt) * 2008-04-11 2021-05-25 Merck Patent Gmbh derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk), seu processo de preparação, e medicamentos

Also Published As

Publication number Publication date
BR112012016330B8 (pt) 2021-05-25
SI2519527T1 (sl) 2014-06-30
CY1114952T1 (el) 2016-12-14
EP2519527A1 (en) 2012-11-07
CN102803269A (zh) 2012-11-28
TW201144318A (en) 2011-12-16
TWI574968B (zh) 2017-03-21
SMT201400013B (it) 2014-05-07
KR101469002B1 (ko) 2014-12-04
CA2784553A1 (en) 2011-07-07
WO2011080277A1 (en) 2011-07-07
US9365584B2 (en) 2016-06-14
IL220432A (en) 2015-02-26
EP2519527B1 (en) 2013-12-18
ME01558B (me) 2014-04-20
RS53282B (en) 2014-08-29
CN102803269B (zh) 2016-01-13
JP5559894B2 (ja) 2014-07-23
JP2013515758A (ja) 2013-05-09
ES2445537T3 (es) 2014-03-03
HRP20140035T1 (hr) 2014-02-14
KR20120120232A (ko) 2012-11-01
EA020588B1 (ru) 2014-12-30
BR112012016330B1 (pt) 2021-03-23
CA2784553C (en) 2014-08-19
MX2012007548A (es) 2012-07-23
PT2519527E (pt) 2014-02-17
AU2010338280B2 (en) 2013-08-22
EA201200975A1 (ru) 2012-12-28
US20130053401A1 (en) 2013-02-28
DK2519527T3 (da) 2014-01-27
ZA201205604B (en) 2013-05-29
PL2519527T3 (pl) 2014-06-30
AU2010338280A1 (en) 2012-07-26

Similar Documents

Publication Publication Date Title
BR112012016330A2 (pt) ativadores de tieno [2, 3-b] piridinadiona de ampk e usos terapêuticos dos mesmos
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
BRPI0918139A2 (pt) composição, alimento medicinal ou funcional, suplemento alimentar ou dietético para tratamento de distúrbios de desenvolvimento pervasivos com terapêuticos redox-ativos e uso
CL2008003473A1 (es) Compuestos derivados de fenilpiperidina sustituidos por heterociclos; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso en el tratamiento del trastorno cardiovasculares, tromboembolicos y tumorales; usos in vitro.
CL2008003116A1 (es) Compuestos heterocíclicos bicíclicos; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento o prevención de enfermedades tales como diabetes, obesidad, trastorno metabólico, enfermedad cardiovascular entre otras.
EA202091999A2 (ru) Применение ингибиторов dpp iv
CL2011001536A1 (es) Compuestos derivados de pirimidin-2-il-1h-indol, inhibidores de la proteina quinasa atr; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos utiles para el tratamiento del cancer.
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
CL2007002121A1 (es) Compuestos derivados de pirazoles, activadores de glucoquinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que comprende dichos compuestos; y uso para el tratamiento de enfermedades y/o trastornos metabolicos, tal como diab
EA201101190A1 (ru) Фармацевтическая композиция, включающая линаглиптин и необязательно ингибитор sglt2, и ее применение
CL2007003523A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
ECSP11011278A (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
BRPI0817503B8 (pt) derivados de purina substituídos por pirimidina, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para a prevenção ou tratamento de uma condição proliferativa
CL2012000754A1 (es) Compuestos derivados de benzoxazepina condensadas con pirazolilo o imidazolilo, inhibidores de la actividad de la quinasa pi3; composicion farmaceutica que comprende un compuesto; y su uso en la preparacion de medicamentos para el tratamiento del cancer.
CL2007001972A1 (es) Ester isopropilico del acido 4-[6-(6-metanosulfonil-2-metilpiridin-3-ilamino)-5-metilpirimidin-4-iloxi]piperidin-1-carboxilico, moduladores del metabolismo; composicion farmaceutica; y su uso para tratar trastornos metabolicos.
CL2007003756A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de proteina quinasas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
CL2007002635A1 (es) Compuestos derivados de quinazolinona e isoquinolinona, moduladores de la actividad del eje hpa; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion relacionado con estres o depresion.
DOP2007000043A (es) Derivados de cromanol sustituidos y su uso
BR112012027197A2 (pt) combinação ou composição farmacêutica, seu uso, kit, e compostos para tratamento de doenças oncológicas e fibróticas
UY31922A (es) Compuestos
AR060786A1 (es) Variaciones cristalinas de (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina
CL2007000781A1 (es) Nanoparticulas que comprenden un inhibidor de quinasa de tirosina receptora del factor de crecimiento derivado de plaquetas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades vasculares, tales como restenosis
BRPI1009781A2 (pt) compostos para o tratamento de distúrbios metabólicos, composição farmacêutica que os compreende e uso dos mesmos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/12/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2703 DE 25-10-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.